Evidence strength for the context described on this page.
PEPTIDE ATLAS / METABOLIC & FAT LOSS / SETMELANOTIDE
EvidenceHigh for approved indicationi
RegulatoryFDA-approvedi
Setmelanotide

A diagnosis-specific obesity therapy for selected rare disorders and acquired hypothalamic obesity.
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read the evidence limits
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
The five facts to know first.
Status is product-, formulation- and indication-specific.
Public education does not establish a personal treatment plan.
Plus 0 research searches. A search link is not a cited study or proof of a claim.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗Where present, the date above records an editorial content review, not medical approval or a live check of every claim. Follow the official product label and regulator links for current status. This page does not establish availability through Modern Bio.
How we describe evidence →OVERVIEW
What Setmelanotide is.
A melanocortin-4 receptor agonist approved for acquired hypothalamic obesity from age 4, and for obesity due to Bardet-Biedl syndrome or specified POMC, PCSK1 or LEPR deficiencies from age 2. It is not approved for common polygenic obesity.
Activates MC4 receptors in the hypothalamic appetite pathway, reducing hunger and supporting energy expenditure when the pathway defect is upstream and responsive.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- Reduced hunger and weight in eligible rare-disease populations
- Targets a defined biological pathway rather than general appetite alone
- Use for ordinary obesity
- Use without genetic or specialist evaluation
- Cosmetic weight loss
Evidence grade: High for approved indication. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
CLINICAL CONTEXT
The decision is individual.
Approval applies to a specific product and indication. A licensed clinician must evaluate whether the exact treatment fits your history, current medications and goals.
Identify the outcome, formulation and population actually studied.
Review benefits, uncertainty, contraindications and better-studied alternatives.
A treatment decision needs a responsible clinician, monitoring and a review date.
This public guide does not provide a dosing, injection or self-treatment protocol. Bring the source links and the exact product into a licensed clinical consultation.
MONITORING
What should be tracked.
- Hunger and weight response
- Skin pigmentation and changing lesions
- Sexual adverse effects and mood symptoms
- Adrenal function and sodium balance when relevant to acquired hypothalamic obesity
SAFETY
Risks, red flags and reasons to avoid it.
- Skin hyperpigmentation and darkening of existing nevi
- Spontaneous erections or sexual adverse reactions
- Depression or suicidal ideation warning
- Acute adrenal insufficiency and sodium imbalance in relevant patients with acquired hypothalamic obesity
- Injection-site reactions
- Use without a qualifying diagnosis
- Unexamined changing skin lesions
- Continuing without specialist reassessment of benefit and tolerability
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
SOURCES & RESEARCH LINKS
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. Vendor and community dosing protocols are excluded from this public source list. These are supporting reading links, not a completed claim-by-claim citation map. Search links can lead to changing results; their presence does not establish that a particular study supports this profile.
PRODUCTS & TREATMENT ACCESS
Use a verified prescription pathway.
Specialty prescription product for specific rare conditions.
It belongs in a peptide atlas because it shows what true precision peptide medicine looks like: diagnosis-specific indications, specialist selection and a regulated product.
Learn now. Verify care separately.
This guide is not a booking or prescribing service. Clinical appointments and prescription decisions are handled separately from this educational Atlas.
Review care readiness and standards →NEXT STEP
Return to metabolic & fat loss peptides.
Explore the category →YOUR NEXT STEP
Ready for a clinician-led plan?
Clinical review determines the appropriate next step. No treatment is guaranteed.
THE CARE PATH
We order your labs
A licensed clinician reviews results and recommends a plan
Rx sent directly to you when appropriate
Care depends on eligibility and clinical judgment. No prescription is guaranteed. This pathway is not a recommendation for the treatment or test discussed in this guide.
Start your lab reviewExplore free educational tools